SOD1 and amyotrophic lateral sclerosis: Although ALS management remains largely focused on supportive care and multidisciplinary interventions, recent therapeutic advances, including gene-targeted therapies such as tofersen for SOD1-related ALS and other emerging disease-modifying approaches, illustrate how treatment strategies are beginning to evolve, particularly for patients with specific genetic subtypes [5].